SCHEMBL9907384

SCHEMBL9907384

[C-]#[N+]c1ccccc1-c1nccc2ccc(C(=O)O)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 1/20 0.46
KMT2A Q03164 3/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 2/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GRIN2D O15399 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2C Q14957 1/20 0.38
KDM4C Q9H3R0 3/20 0.38
KDM4E B2RXH2 4/20 0.37
KDM6B O15054 2/20 0.37
KDM4A O75164 2/20 0.37
KDM5C P41229 2/20 0.37
KDM2A Q9Y2K7 2/20 0.37
KDM3A Q9Y4C1 2/20 0.37
TTR P02766 1/20 0.36
CSNK2A2 P19784 3/20 0.36
CSNK2B P67870 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907378 0.86 ALOX15 (0.41) RAB9AHTTKDM4CKDM4EKDM6B
SCHEMBL9907395 0.84 PLAU (0.43) PLAURAB9AKDM4CKDM4ETTR
SCHEMBL9907915 0.84 HTR5A (0.49) PLAU
SCHEMBL16502684 0.79 PLAU (0.50) PLAUKMT2ARAB9AMEN1PKM
SCHEMBL9907345 0.79 KDM4C (0.41) PLAUKMT2ARAB9AMEN1PKM
SCHEMBL9907335 0.78 PLAU (0.55) PLAURAB9AGRIN2DGRIN2AGRIN2C
SCHEMBL9909158 0.78 KMT2A (0.46) PLAUKMT2ARAB9AMEN1PKM
SCHEMBL9907436 0.77 PLAU (0.43) PLAUKDM4CKDM4ACSNK2A2CSNK2B
SCHEMBL9907382 0.76 PLAU (0.47) PLAUKMT2ARAB9AMEN1PKM
SCHEMBL10030438 0.73 CSNK2A2 (0.41) KMT2ARAB9AMEN1PKMHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E PLAU 3322/4885KMT2A 1729/4885RAB9A 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.